Mamedica Secures £4.5 Million Investment to Transform Cannabis Healthcare in the UK

Mamedica Secures Major Funding to Expand Cannabis Healthcare Services

Mamedica, the foremost provider of cannabis-based prescription medicines in the UK, has announced a significant funding round totaling £4.5 million. This investment was led by Casa Verde, a renowned U.S.-based venture capital firm specializing in cannabis. With an eye towards facilitating wider access to cannabis-care solutions, this investment marks a crucial step towards achieving Mamedica's ambitious goals in the burgeoning UK medical cannabis market.

Since its inception in 2022, Mamedica has aimed to offer comprehensive and trustworthy treatment options for various chronic and neurological conditions, such as pain, anxiety, ADHD, and depression. By integrating technology with healthcare, Mamedica enables patients to receive tailored care in a convenient manner—remote consultations with specialist clinicians and next-day delivery of prescribed medication via secure courier channels.

In just a couple of years, Mamedica has already made significant inroads into the healthcare landscape. The clinic has treated over 10,000 patients, with approximately 7,500 actively receiving care. Notably, they have reported a remarkable 1,250% patient growth in 2023 and an impressive 154% in the following year. The recent increase in interest suggests that the UK medical cannabis industry is on track to reach an annual valuation of £1 billion by 2028.

Casa Verde’s Strategic Backing

Casa Verde, the venture capital firm behind this latest funding round, has a strong track record of investing in major cannabis companies like Dutchie and Leaflink. Karan Wadhera, Managing Partner at Casa Verde, expressed excitement about partnering with Mamedica. He remarked, "As the UK cannabis market enters a period of rapid growth, Mamedica's digital-first, patient-centric model sets the standard for care in the UK."

This influx of capital will be pivotal in scaling Mamedica's operations. It will allow the company to optimize its in-house supply chain, expand its clinical network, and enhance its proprietary digital healthcare platform. These advancements are essential for improving efficiency, ensuring continuity of care for patients, and educating the public about the integration of medical cannabis into conventional healthcare settings.

Future Outlook

Mamedica's CEO and founder, Jon Robson, stated, "This funding marks a pivotal milestone in Mamedica's mission to transform patient care in the UK. The backing of Casa Verde and our private investors validates our innovative approach and enables us to accelerate access to high-quality, regulated treatment."

The company’s commitment to patient care, safety, and satisfaction, coupled with its proprietary technology and a team of expert clinicians and pharmacists, positions it well for future growth. As it prepares to tackle the challenges of scaling and expanding its services, Mamedica is laying down a robust foundation for both patients and the wider cannabis healthcare ecosystem.

Conclusion

In summary, Mamedica’s securing of £4.5 million in funding opens up new avenues for delivering effective healthcare solutions to those in need. As the UK medical cannabis market continues to grow, Mamedica is poised to lead the charge in offering innovative solutions to improve patient lives. This landmark investment not only enhances Mamedica's capabilities but also signifies a progressive shift towards integrating cannabis healthcare into mainstream practices.